<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471562</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000543744</org_study_id>
    <secondary_id>CCCWFU-99206</secondary_id>
    <secondary_id>CCCWFU-99206/Ang 1-7</secondary_id>
    <secondary_id>CCCWFU-IRB00001136</secondary_id>
    <nct_id>NCT00471562</nct_id>
    <nct_alias>NCT01581268</nct_alias>
  </id_info>
  <brief_title>Angiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors</brief_title>
  <official_title>Phase I Clinical Trial of Angiotensin 1-7 for Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Angiotensin-(1-7) may stop the growth of solid tumors by blocking blood flow to&#xD;
      the tumor.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of angiotensin-(1-7)&#xD;
      in treating patients with metastatic or unresectable solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of therapeutic angiotensin-(1-7) in patients with&#xD;
           metastatic or unresectable solid tumors.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine tumor response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive therapeutic angiotensin-(1-7) subcutaneously on days 1-5. Courses repeat&#xD;
      every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of therapeutic angiotensin-(1-7) until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first 3 weeks of&#xD;
      study therapy. At least 6 patients are treated at the MTD.&#xD;
&#xD;
      Blood samples are collected from patients after the first and fifth doses of the study drug&#xD;
      for pharmacokinetic correlative studies.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>105 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (complete or partial response) as measured by RECIST criteria</measure>
    <time_frame>105 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic angiotensin-(1-7)</intervention_name>
    <description>sequentially increasing doses 50-1000 mcg/kg</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced solid tumor meeting 1 of the&#xD;
             following criteria:&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
               -  Unresectable disease&#xD;
&#xD;
          -  Standard curative or palliative measures do not exist or are no longer effective&#xD;
&#xD;
          -  Measurable or nonmeasurable disease&#xD;
&#xD;
               -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by&#xD;
                  conventional techniques or ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  Nonmeasurable disease, defined as all other lesions, including small lesions&#xD;
                  (i.e., ≥ 1 unidimensionally measurable lesion &lt; 20 mm by conventional techniques&#xD;
                  or &lt; 10 mm by spiral CT scan) and truly nonmeasurable lesions, including any of&#xD;
                  the following:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural or pericardial effusion&#xD;
&#xD;
                    -  Lymphangitis cutis or pulmonis&#xD;
&#xD;
                    -  Abdominal masses not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  No lung cancer with recent hemoptysis&#xD;
&#xD;
          -  No brain metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 4 weeks&#xD;
&#xD;
          -  No evidence of bleeding diathesis&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Creatinine clearance &gt; 30 mL/min&#xD;
&#xD;
          -  Bilirubin &lt; 2 mg/dL&#xD;
&#xD;
          -  AST and ALT &lt; 3 times upper limit of normal&#xD;
&#xD;
          -  No concurrent uncontrolled illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Uncontrolled hypertension or hypotension&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude informed consent or&#xD;
             study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy or chemotherapy (6 weeks for melphalan,&#xD;
             nitrosoureas, or mitomycin C)&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent angiotensin-converting enzyme inhibitors or angiotensin II receptor&#xD;
             blockers&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. Jeffrey Petty, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res. 2009 Dec 1;15(23):7398-404. doi: 10.1158/1078-0432.CCR-09-1957. Epub 2009 Nov 17.</citation>
    <PMID>19920106</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>May 8, 2007</study_first_submitted>
  <study_first_submitted_qc>May 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2007</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin I (1-7)</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

